OGT and hepatocellular carcinoma: A recent report revealed that treating hepatocellular carcinoma cells with a ferroptosis inducer (e.g., erastin or RSL3) increases OGT activity, while not affecting OGT abundance or UDP-GlcNAc levels (18).